AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 108 filers reported holding AVROBIO INC in Q4 2020. The put-call ratio across all filers is 2.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,005 | -29.5% | 5,198 | -56.5% | 0.00% | – |
Q2 2023 | $11,357 | +189183.3% | 11,955 | +88.1% | 0.00% | – |
Q1 2023 | $6 | -45.5% | 6,355 | -58.0% | 0.00% | – |
Q4 2022 | $11 | -99.8% | 15,138 | +39.5% | 0.00% | – |
Q3 2022 | $7,000 | -30.0% | 10,849 | +4.4% | 0.00% | – |
Q2 2022 | $10,000 | -44.4% | 10,387 | -24.0% | 0.00% | – |
Q1 2022 | $18,000 | -82.5% | 13,662 | -49.0% | 0.00% | -100.0% |
Q4 2021 | $103,000 | +171.1% | 26,764 | +290.4% | 0.00% | +100.0% |
Q3 2021 | $38,000 | +40.7% | 6,855 | +124.9% | 0.00% | 0.0% |
Q2 2021 | $27,000 | +35.0% | 3,048 | +94.9% | 0.00% | – |
Q1 2021 | $20,000 | -23.1% | 1,564 | -16.7% | 0.00% | -100.0% |
Q4 2020 | $26,000 | 0.0% | 1,878 | -8.8% | 0.00% | – |
Q3 2020 | $26,000 | -74.0% | 2,059 | -64.0% | 0.00% | -100.0% |
Q2 2020 | $100,000 | +733.3% | 5,720 | +702.2% | 0.00% | +300.0% |
Q1 2020 | $12,000 | -80.3% | 713 | -76.3% | 0.00% | -80.0% |
Q4 2019 | $61,000 | +117.9% | 3,009 | +52.3% | 0.01% | +150.0% |
Q3 2019 | $28,000 | -20.0% | 1,976 | -5.8% | 0.00% | -33.3% |
Q4 2018 | $35,000 | – | 2,097 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |